Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

LivaNova PLC developed the new cardio-pulmonary system based on feedback from more than 300 perfusionists.

Although advanced imaging exams have proven benefits in defining disease severity, new data indicate that more sophisticated studies might not impact outcomes as much as previously thought. 

New research presented at the American College of Cardiology’s annual meeting has shown that long-term intermittent fasting improved outcomes for individuals with COVID-19 who also have a history of heart disease.

ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

Here are links to more information on every late-breaking presentation at ACC.23.

For patients who were hospitalized, but not yet in the ICU, those randomly assigned a higher-dose of anticoagulants had lower 30-day mortality risk than those on a lower dose. 

Published in JACR, the new white paper outlines four areas of consensus between the two specialties. 

Laura Perryman, the former chief of Florida-based Stimwave, allegedly created a non-functioning “dummy device” that was used to treat patients suffering from chronic pain.